New Market Study, "Czech Republic Pharmaceuticals & Healthcare Report Q3 2013", Has Been Published
The Ministry of Health's decision to reimburse the state insurer more for taking on expensive patients suggests state favouritism, but given the VzP's longer list of high-risk patients, it is understandable. The fact that private insurers have not diversified their pools of patients has meant that the most demanding patients have ended up with the VzP, contributing to its significant debts. The insurance system must draw from other European countries, where risk is equalised to ensure coverage for all patients.
View full press release